ArticleAdvanced biomedical research2025
Assessing the Biological Markers of MiRNA-9 and 192 Expression Levels in Cervical Cancer.
Article in Advanced biomedical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Various risk factors thought to impact cervical cancer progression. One way these factors influence cancer development is through changes in the microRNA's expression, which are small, non-coding, single-stranded RNA molecules around 20-23 nucleotides long. In cervical cancer, specific miRNAs, notably miRNA-9 and miRNA-192, are gaining attention as potential clinical biomarkers. Materials and Methods: RNA was extracted from cervical intraepithelial neoplasia grade I, II, and III (CIN I, CIN II, and CIN III) tissues, as well as their adjacent normal tissues, to compare the expression levels of miRNA-9 and miRNA-192 as potential biomarkers. The extracted RNAs were then converted to cDNA for evaluation using quantitative PCR (qPCR). Results: Pathological analysis revealed that 80% of patients with cervical cancer and CIN III tissues were diagnosed with squamous cell carcinoma, while the proportions for adenocarcinoma and adenosquamous cell carcinoma were 13.4% and 6.6%, respectively. Our data indicated a significant increase in the expression of miRNA-192-5p ( Conclusions: miRNA-9 and miRNA-192 may serve as promising biomarkers for cervical cancer, given their elevated expression levels in the both cervical cancer and CIN III tissues. This expression pattern implies that they could aid in detecting early stages of cervical cancer progression, potentially improving early diagnosis and monitoring. However, further studies are essential to confirm these preliminary findings and validate their clinical relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.